Technologies

The present invention relates to the biomedical sector of the treatment of lung diseases and related symptoms. In particular, the present invention provides compositions and methods based on the use of selected polymeric biomaterials, in combination with stem cells and/or their secretome, capable of synergistically improving the development, regeneration and repair of chronic lung injuries and related symptoms.

The dramatic global health emergency due to the SARS-CoV-2 pandemic requires new diagnostic devices capable of identifying the presence of virus particles in patient biological samples. In this direction, the development of an innovative low-cost test, which provides the result within a few minutes, which is reproducible and which can reveal the direct presence of even a few viral particles, would be of fundamental importance for the monitoring and containment of the pandemic.

The proposed system is based on a high-resolution electrocardiograph in which the electrodes are positioned on maternal abdomen. The acquired signals are processed using a completely unsupervised software for fetal ECG extraction based on independent component analysis, maternal ECG canceling and a quality index optimization. The electrocardiograph is constituted by a light-weight and light-dimension portable unit, which acquires the signals and transmit them to a computer where the analysis software runs.

IMM has developed tactile sensors for the detection of objects and surface and for the handling of objects with humanoid robots (e-skin). These devices can be integrated on ultra-flexible and high conformable substrates and they can be used for multiple applications: 1) for a correct interaction with objects distributed in complex environment; 2) for a safe short-range interaction between humanoid robot and humans; 3) for fabricating smart wearables for the detection of biometric parameters (e.g. heartbeat); 4) for remotely control rovers with wearable gadgets.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.